{"publication_id":"1a265041-dcba-4d47-9a2a-af0e73104267","content_hash":"sha256:6dbe18f2f602bdea633e218dd426957a6f277d6a8ec2f80eeb2d991c6ff684a6","nodes":[{"id":"1a265041-dcba-4d47-9a2a-af0e73104267","type":"publication","title":"Bounded Senolytic signal: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leuke"},{"id":"claim_1","type":"claim","text":"The direct receipts support a narrow working claim: Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia‐free state (MLFS); Responses were observed in 4 (50%) of 8 RUNX1‐mutated patients. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction."},{"id":"claim_4","type":"claim","text":"_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._"},{"id":"claim_5","type":"claim","text":"`fact_id=90736` (`B_context`) — Significant increases in epigenetic age acceleration were observed in first-generation epigenetic clocks and mitotic clocks at 3 and 6 months doi=10.18632/aging.205581"},{"id":"claim_6","type":"claim","text":"`fact_id=164159` (`A_core`) — related mortality was not increased (2%) Source: A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma"},{"id":"source_1","type":"source","study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","year":2017,"doi":"10.1002/ajh.25000","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","year":2023,"doi":"10.1200/jco.23.01075","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","year":2020,"doi":"10.1002/ajh.25978","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","year":2018,"doi":"10.1182/blood-2018-08-868752","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","year":2024,"doi":"10.1182/blood-2024-204375","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions","year":2024,"doi":"10.18632/aging.205581","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"}],"edges":[{"from":"1a265041-dcba-4d47-9a2a-af0e73104267","to":"claim_1","type":"contains_claim"},{"from":"1a265041-dcba-4d47-9a2a-af0e73104267","to":"claim_2","type":"contains_claim"},{"from":"1a265041-dcba-4d47-9a2a-af0e73104267","to":"claim_3","type":"contains_claim"},{"from":"1a265041-dcba-4d47-9a2a-af0e73104267","to":"claim_4","type":"contains_claim"},{"from":"1a265041-dcba-4d47-9a2a-af0e73104267","to":"claim_5","type":"contains_claim"},{"from":"1a265041-dcba-4d47-9a2a-af0e73104267","to":"claim_6","type":"contains_claim"}],"screening":{"identified":6,"screened":6,"excluded":0,"included":6,"included_or_retained":6,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"6 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}